SCHEMBL5828047

SCHEMBL5828047

CC(=O)OC[C@H]1O[C@@H](n2cc(C3=C(c4c[nH]c5ncccc45)C(=O)N(C)C3=O)c3ccccc32)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
THRB P10828 1/20 0.45
HIF1A Q16665 1/20 0.45
PRKCA P17252 2/20 0.41
AKT1 P31749 2/20 0.41
PTK2 Q05397 2/20 0.41
TGM2 P21980 1/20 0.41
GAPDH P04406 1/20 0.41
PTGS2 P35354 1/20 0.39
PIM1 P11309 1/20 0.39
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPT P10636 3/20 0.38
HPGD P15428 3/20 0.38
TP53 P04637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
TSHR P16473 1/20 0.38
PRKAB2 O43741 1/20 0.38
PRKAG1 P54619 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5827541 0.92 LMNA (0.47) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5827873 0.89 LMNA (0.39) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5827622 0.86 LMNA (0.42) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5828932 0.85 LMNA (0.45) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5828229 0.83 PTGS2 (0.45) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5828106 0.82 LMNA (0.41) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5828429 0.80 LMNA (0.41) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL6197547 0.79 LMNA (0.47) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5828426 0.77 PTGS2 (0.43) LMNASMN1; SMN2THRBHIF1APRKCA
SCHEMBL5828022 0.76 LMNA (0.39) LMNASMN1; SMN2THRBHIF1APRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001906-B2 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives LES LABORATOIRES SERVIER (FR) 2006-02-21 US disclosed
US-20040152721-A1 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives LES LABORATOIRES SERVIER (FR) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152721-A1 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives PYM1, PNPO, IDO1 LMNA 4488/4885SMN1; SMN2 4557/4885THRB 2620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.